Venrock Opportunities Fund L.P. 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 5:53 pm Sale |
2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Opportunities Fund L.P. | 1,882,615 2.900% |
-941,306 (-33.33%) |
Filing |
| 2023-12-08 4:17 pm Purchase |
2023-11-01 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Opportunities Fund L.P. | 2,823,921 5.200% |
2,823,921 (New Position) |
Filing |